Helicase-like transcription factor expression is associated with a poor prognosis in Non-Small-Cell Lung Cancer (NSCLC).

Fiche publication

Date publication

avril 2018

Journal

BMC cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MASCAUX Céline

Tous les auteurs :
Dhont L, Pintilie M, Kaufman E, Navab R, Tam S, Burny A, Shepherd F, Belayew A, Tsao MS, Mascaux C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29661164

Résumé

The relapse rate in early stage non-small cell lung cancer (NSCLC) after surgical resection is high. Prognostic biomarkers may help identify patients who may benefit from additional therapy. The Helicase-like Transcription Factor (HLTF) is a tumor suppressor, altered in cancer either by gene hypermethylation or mRNA alternative splicing. This study assessed the expression and the clinical relevance of wild-type (WT) and variant forms of HLTF RNAs in NSCLC.